Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt
1 other identifier
observational
50
0 countries
N/A
Brief Summary
determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 22, 2024
CompletedFirst Posted
Study publicly available on registry
April 1, 2024
CompletedStudy Start
First participant enrolled
April 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedApril 1, 2024
March 1, 2024
2 years
March 22, 2024
March 29, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
assess the outcome of pediatric patients with HL treated with risk- and response-adjusted therapy
determine if radiotherapy could be safely omitted for early responder patients without compromising outcome, it can be assessed by decrease in lymph node volume ,Volumes are approximated as ellipsoids. If a, b, c denote the principal axes of the ellipsoid the volume is calculated as V= (a x b x c)/2
2 years
Interventions
radiotherapy
Eligibility Criteria
Infants and children around age of (1month to 18 years old) admitted with hodgkin lymphoma in a period of 2 years
You may qualify if:
- Previously untreated patients younger than 18 years old with classical Hodgkin lymphoma
You may not qualify if:
- Patients aged more than 18 years old.
- Patients who died early at presentation before starting chemotherapy
- diagnosis of nodular lymphocytic predominant Hodgkin lymphoma
- previous chemotherapy or radiotherapy other (simultaneous) malignancies
- severe concomitant diseases (eg, immune deficiency syndrome); or known HIV positive.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principle investigator
Study Record Dates
First Submitted
March 22, 2024
First Posted
April 1, 2024
Study Start
April 1, 2024
Primary Completion
April 1, 2026
Study Completion
April 1, 2026
Last Updated
April 1, 2024
Record last verified: 2024-03